, Tracking Stock Market Picks
Enter Symbol:

down 9.25 %

ONCOTHYREON (ONTY) rated Buy with price target $6 by Stifel

Posted on: Thursday,  Mar 13, 2014  8:25 AM ET by Stifel

Stifel rated Buy ONCOTHYREON (NASDAQ: ONTY) on 03/13/2014, when the stock price was $3.89. Since then,
ONCOTHYREON has lost 9.25% as of 01/14/2016's recent price of $3.53.
If you would have followed this Stifel's recommendation on ONTY, you would have lost 9.25% of your investment in 672 days.

Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company. The Company focuses primarily on the development of therapeutic products for the treatment of cancer. The Company?s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Oncothyreon?s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer (NSCLC). Oncothyreon has an exclusive, worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Its pipeline of product candidates is consisted of cancer vaccines and small molecule candidates. The Company?s wholly owned subsidiaries include Oncothyreon Canada Inc., Biomira Management Inc., ProlX Pharmaceuticals Corporation, Biomira International Inc., Biomira BV and Oncothyreon Luxembourg.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/13/2014 8:25 AM Buy
3.89 6.00
as of 10/17/2014
1 Week down  -3.93 %
1 Month down  -14.50 %
3 Months down  -35.71 %
1 YTD down  -56.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy